Ribocure Pharmaceuticals
CompanySweden
Ribocure Pharmaceuticals develops 2 assets, the furthest in phase 2 (Vortosiran in non-valvular atrial fibrillation). Mostly oligonucleotide acting on F11, lipid and ceramide metabolism and INHBE; based in Sweden.
- 2
- Assets
- Furthest stage
- Phase 2
- 1
- Trial
- 3
- Signals
Pipeline
2Silences hepatic factor XI expression to reduce coagulation and thromboembolic risk.
Phase 2, Oligonucleotide, F11, non-valvular atrial fibrillation
siRNA targeting INHBE to regulate metabolic processes.
Phase 1, Oligonucleotide, Lipid and ceramide metabolism, INHBE, obesity, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials1
- Signals3
- Similar companies6